Maxim analyst Michael Okunewitch initiated coverage of MediWound with a Buy rating and $25 price target. The company’s bromelain-based platform seeks to address unmet needs in wound care and dermatologic cancer, the analyst tells investors in a research note. Okunewitch believes that MediWound’s revenue for NexoBrid – the treatment for severe burns with a targeted PDUFA date of January 1 2023 – should build, providing a "valuation catalyst". The analyst adds that the company’s EscharEx for chronic wound care set for a phase 3 trial in the first half of 2023 is a "higher value opportunity" in the $2B market.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See Insiders’ Hot Stocks on TipRanks >>
Read More on MDWD:
- MediWound Expands NexoBrid’s Global Presence with Marketing Approval in Japan
- MediWound price target raised to $63 from $9 at Oppenheimer
- MediWound Strengthens European Presence of NexoBrid®
- MediWound announces marketing approval of NexoBrid in Switzerland
- MediWound Announces Positive Results in U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma